Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2015 Apr;60(4):806-9.
doi: 10.1007/s10620-015-3535-x.

Hepatitis C direct antiviral drugs and hepatic decompensation in patients with advanced cirrhosis: culprit or innocent bystander?

Varun Saxena  1 , Norah A Terrault
Affiliations
Editorial

Hepatitis C direct antiviral drugs and hepatic decompensation in patients with advanced cirrhosis: culprit or innocent bystander?

Varun Saxena et al. Dig Dis Sci. 2015 Apr.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384:1756–1765. - PubMed
    1. Stine JG, Intagliata N, Shah NL, et al. Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis. Dig Dis Sci. doi: 10.1007/s10620-014-3422-x. Epub ahead of print. - DOI - PMC - PubMed
    1. Danan G, Benichou C. Causality assessment of adverse reactions to drugs–I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46:1323–1330. - PubMed
    1. Sofosbuvir [package insert] Foster City, CA: Gilead Sciences; 2013.
    1. Simeprevir [package insert] Titusville, NJ: Janssen Therapeutics; 2013.

MeSH terms

LinkOut - more resources